
Spike Protein Luciferase
Human Anti centriole and centrosome antibody IgG ELISA kit |
|||
E01A0698-192T | BlueGene | 192 tests | EUR 1524 |
Description: A competitive ELISA for quantitative measurement of Human Anti centriole and centrosome antibody IgG in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
Human IgG antibody Laboratories manufactures the spike protein luciferase reagents distributed by Genprice. The Spike Protein Luciferase reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact Spike Protein. Other Spike products are available in stock. Specificity: Spike Category: Protein Group: Luciferase
True north Cryobox 15mLBlue |
||
Scientific Laboratory Supplies | PK10 | EUR 212.4 |
True north Cryobox 50mLNatural |
||
Scientific Laboratory Supplies | PK10 | EUR 210 |
True north Cryobox 50mLBlue |
||
Scientific Laboratory Supplies | PK10 | EUR 210 |
True north Cryobox1.5/2mLNatural |
||
Scientific Laboratory Supplies | PK10 | EUR 162 |
True north Cryobox1.5/2.0mLGreen |
||
Scientific Laboratory Supplies | PK10 | EUR 162 |
Human true insulin,TI ELISA Kit |
||
SunredBio | 96 tests | EUR 528 |
Description: A quantitative ELISA kit for measuring Human in samples from biological fluids. |
Human true insulin,TI ELISA Kit |
||
ChemNorm | 96T | EUR 567.6 |
Spike (BA.4/5, Omicron Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) |
|||
78644-2 | BPS Bioscience | 500 µl x 2 | EUR 3995 |
Description: The Spike protein of BA.4 and BA.5 variants of SARS-CoV-2 have identical mutations. In this datasheet, the spike protein of BA.4 and BA.5 are referred to as BA.4/5._x000D_The Spike (BA.4/5, Omicron Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) was produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1 containing all the Omicron BA.4/5 mutations; see below for details) as the envelope glycoprotein instead of VSV-G. The pseudovirions contain the firefly luciferase gene, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (BA.4/5 Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) can be used to measure the activity of a neutralizing antibody against SARS-CoV-2 BA.4/5 variant in a Biosafety Level 2 facility._x000D_The Spike (BA.4/5 Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) has been validated for use with target cells Vero-E6 and ACE2-HEK293 (BPS Bioscience #79951). Spike VSV Delta G is preferred for use in cells such as Vero-E6 and Calu-3._x000D_Spike Mutations in BA.4/5, Omicron Variant:_x000D_Del69-70, T19I, LPPA24-27S, G142D, V213G, G339D, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, L452R, S477N, T478K, E484A, F486V, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H, N969K |
Spike (BA.1.1, Omicron Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter)-100 µl |
|||
78641-1 | BPS Bioscience | 100 µl | EUR 795 |
Description: The Spike (BA.1.1, Omicron Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) was produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1 containing all the Omicron BA.1.1 mutations; see below for details) as the envelope glycoprotein instead of VSV-G. The pseudovirions contain the firefly luciferase gene; therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (BA.1.1 Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) can be used to measure the activity of a neutralizing antibody against SARS-CoV-2 BA.1.1 variant in a Biosafety Level 2 facility.As shown in Figures 1 and 2, the Spike (BA.1.1 Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) has been validated for use with target cells Vero-E6 and ACE2-HEK293 (BPS Bioscience #79951). Spike VSV Delta G is preferred over lentiviral-based spike pseudoviruses for use in cells such as Vero-E6 parental cells.Spike Mutations in BA.1.1 Omicron Variant:A67V, Δ69-70, G142D, Δ143-145, Δ211, L212I, ins214EPE, G339D, R346K, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H, N764K, D796Y, N856K, T95I, Q954H, N969K, L981F |
Spike (BA.1.1, Omicron Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter)-500 µl x 2 |
|||
78641-2 | BPS Bioscience | 500 µl x 2 | EUR 3995 |
Description: The Spike (BA.1.1, Omicron Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) was produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1 containing all the Omicron BA.1.1 mutations; see below for details) as the envelope glycoprotein instead of VSV-G. The pseudovirions contain the firefly luciferase gene; therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (BA.1.1 Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) can be used to measure the activity of a neutralizing antibody against SARS-CoV-2 BA.1.1 variant in a Biosafety Level 2 facility._x000D_As shown in Figures 1 and 2, the Spike (BA.1.1 Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) has been validated for use with target cells Vero-E6 and ACE2-HEK293 (BPS Bioscience #79951). Spike VSV Delta G is preferred over lentiviral-based spike pseudoviruses for use in cells such as Vero-E6 parental cells._x000D_Spike Mutations in BA.1.1 Omicron Variant:_x000D_A67V, Δ69-70, G142D, Δ143-145, Δ211, L212I, ins214EPE, G339D, R346K, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H, N764K, D796Y, N856K, T95I, Q954H, N969K, L981F |
SARS-CoV Spike Protein |
|||
abx060655-1mg | Abbexa | 1 mg | EUR 2030.4 |
SARS-CoV spike protein Antibody |
|||
abx023139-100ug | Abbexa | 100 ug | EUR 1028.4 |
SARS-CoV spike protein Antibody |
|||
abx023143-100ug | Abbexa | 100 ug | EUR 1028.4 |
COVID-19 Spike Protein a.a. 1000-12000 |
|||
00223-V-100ugvial | Virogen | 100 ug/vial | EUR 150 |
Description: COVID-19 Spike Protein a.a. 1000-12000 |
Recombinant SARS Spike gp C Protein |
|||
VAng-Lsx0072-inquire | Creative Biolabs | inquire | Ask for price |
Description: SARS Spike glycoprotein C, recombinant protein from E. coli. |
Luciferase protein (His tag) |
|||
80R-1462 | Fitzgerald | 100 ug | EUR 366 |
Description: Purified recombinant firefly Luciferase protein |
Anti-MERSC-CoV Spike Protein antibody |
|||
STJ140102 | St John's Laboratory | 150 µg | EUR 277.2 |
Description: Goat polyclonal to Spike protein of Middle East respiratory Syndrome coronavirus. Coronaviruses access host cells by membrane fusion, a process mediated by specific fusion or “spike” proteins on the virion, often activated by cellular proteases. |
MERS-CoV Spike protein (aa 383-502) [Fc] |
|||
DAG-H10297 | Creative Diagnostics | 20µg | EUR 868.8 |
MERS-CoV Spike protein (aa 367-606) [Fc] |
|||
DAG-H10302 | Creative Diagnostics | 20µg | EUR 868.8 |
COVID-19 Spike Protein a.a. 800 to 1000 |
|||
00222-V-100ugvial | Virogen | 100 ug/vial | EUR 150 |
Description: COVID-19 Spike Protein a.a. 800 to 1000 |
MERS-CoV Spike protein (aa 1-1297) [His] |
|||
DAG-H10300 | Creative Diagnostics | 20µg | EUR 868.8 |
MERS-CoV Spike Protein (aa 367-606) [His] |
|||
DAGB201 | Creative Diagnostics | 20 µg | EUR 868.8 |
MERS Spike S1 Recombinant protein |
|||
39-102 | ProSci | 0.1 mg | EUR 556.8 |
Description: Since April 2012, cases of the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) have been identified in the following countries: Saudi Arabia, Qatar, Jordan, the United Arab Emirates, Oman, Kuwait, Yemen, Lebanon, Iran, Algeria, the United Kingdom, France, Italy, Greece, Germany, the Netherlands, Austria, Tunisia, Egypt, Malaysia, Turkey and the United States of America. Coronaviruses are the cause of the common cold, SARS (severe acute respiratory syndrome) and other severe illnesses with high mortality rates, all are classified into coronavirus family. MERS-CoV is a new type of SARS found in the coronavirus family causing severe pneumonia with sudden and serious respiratory illness with high mortality rates as well. Since January 27th 2015, the WHO has reported 956 human cases, including 351 deaths. More cases of the new coronavirus strain are expected. Like in other coronaviruses, large surface spike glycoprotein is a central structural protein of this virus; it is located above the virion surface to bind and enter into the target cell. Spike protein has 2 domains- S1 and S2. The S1 domain is responsible for cellular tropism and interaction with target cell, while the S2 domain is responsible for membrane fusion. The C-terminal of S1 domain contains a receptor binding domain, and is also a potential target for vaccine development and an antigen for diagnosis. |
Recombinant SARS Spike Protein (aa 1-1190) [His] |
|||
VAng-Lsx0063-inquire | Creative Biolabs | inquire | Ask for price |
Description: SARS Spike protein (aa 1-1190) [His], recombinant protein from HEK 293 cells. |